6.3 Rh System
Key Takeaways
- RHD and RHCE are separate, highly homologous genes on chromosome 1p36.11; unequal recombination between flanking 'Rhesus box' sequences commonly deletes the entire RHD gene, producing the classic Rh-negative phenotype.
- Weak D (a quantitative reduction in D antigen density with all epitopes intact) is genetically and clinically distinct from partial D (a qualitative loss of specific D epitopes that can trigger alloimmunization).
- Molecularly confirmed weak D types 1, 2, 3, 4.0, and 4.1 can be managed safely as RhD-positive without RhIG or RhD-negative blood, per current AABB/CAP/ACOG/ARC joint guidance.
- DVI, the most clinically important partial D, is typically labeled RhD-positive as a donor phenotype but managed as RhD-negative (with RhIG eligibility) as a recipient or obstetric patient, because DVI individuals can form alloanti-D.
- Rh-null phenotype arises either from RHAG (regulator-type) or RH-locus (amorph-type) mutations, causes chronic hemolytic anemia with stomatocytosis, and can lead to anti-Rh29, which is incompatible with virtually all red cells except other Rh-null units.
Rh System
Quick Answer: The Rh system is controlled by two adjacent, highly homologous genes — RHD and RHCE — on chromosome 1p36.11. RHD presence or absence determines D positivity; RHCE determines the C/c and E/e antigens through single amino acid substitutions. The exam-critical distinction is between weak D (quantitatively reduced but complete D antigen) and partial D (qualitatively altered D missing specific epitopes), because the two categories carry opposite transfusion and obstetric management rules.
Two Genes, One Antigen Family
RHD and RHCE lie in tandem on the short arm of chromosome 1, each spanning roughly 75 kb and containing 10 exons, and they are approximately 97% identical in sequence — a homology so high that it drives much of Rh genetic complexity. The C/c polymorphism arises from four linked single-nucleotide changes that together produce one critical amino acid difference (serine versus proline at position 103); the E/e polymorphism arises from a single nucleotide change producing one amino acid difference (alanine versus proline at position 226). D positivity or negativity, in contrast, is usually not a simple point mutation at all: in most Rh-negative individuals of European ancestry, the entire RHD gene is deleted through unequal homologous recombination between two nearly identical 9 kb 'Rhesus box' sequences that flank RHD. In many Rh-negative individuals of African ancestry, RHD is not deleted but is instead present as an inactive pseudogene, RHDψ, silenced by an internal stop codon and a 37-base-pair insertion — a pseudogene that produces no D antigen but that molecular assays must be specifically designed to recognize, or they risk misreporting an inactive RHDψ as an active RHD gene.
Haplotypes and Nomenclature Systems
Because RHD and RHCE are inherited together on the same chromosome far more often than they recombine, specific combinations (haplotypes) occur at characteristic population frequencies. Three parallel naming systems remain in everyday use, and SBB candidates must translate fluently among them:
| Fisher-Race Haplotype | Wiener Symbol | Antigens Present | Approx. Frequency (European-ancestry population) |
|---|---|---|---|
| DCe | R1 | D, C, e | ~42% |
| dce | r | c, e (no D) | ~37% |
| DcE | R2 | D, E, c | ~14% |
| Dce | R0 | D, e, c | ~4% |
| dCe | r' | C, e (no D) | ~2% |
| dcE | r'' | E, c (no D) | <1% |
| DCE | RZ | D, C, E | Rare |
The Rosenfield numeric system (Rh1 = D, Rh2 = C, Rh3 = E, Rh4 = c, Rh5 = e) and the ISBT 004 system provide a third, standardized cross-reference used especially when communicating with reference laboratories and rare-donor registries. Population frequencies differ substantially by ancestry — for example, Rh-negative frequency is roughly 15% in people of European ancestry, roughly 3-8% in people of African ancestry (where the RHDψ pseudogene also complicates simple D-negative counts), and under 1-2% in most Asian populations — a range the SBB exam expects you to apply when reasoning about rare-unit sourcing.
Weak D versus Partial D — the Central SBB Decision
Weak D is a quantitative phenomenon: missense mutations, often in the intracellular or transmembrane portions of the RHD protein, reduce how much D antigen reaches the cell surface, but the full complement of D epitopes is still present, just at lower density. Because every epitope is present, most weak D types are not considered at risk of stimulating alloanti-D production.
Partial D is a qualitative phenomenon: the RHD protein is missing one or more specific epitopes from the normal D mosaic, most often because a segment of RHD sequence has been replaced by the corresponding RHCE sequence through gene conversion. Because specific epitopes are genuinely absent, a partial D individual exposed to normal D-positive red cells can recognize the missing epitopes as foreign and produce a true alloanti-D. DVI is the classic, clinically important partial D: DVI red cells react with most current anti-D reagent blends and are therefore typically labeled RhD-positive as a donor phenotype, yet a DVI recipient or obstetric patient should be managed as RhD-negative — including RhIG eligibility during pregnancy — precisely because that person can form alloanti-D against the D epitopes their own red cells lack.
| Category | Antigen Pattern | Donor Labeling | Recipient / OB Management |
|---|---|---|---|
| Weak D types 1, 2, 3, 4.0, 4.1 | Reduced density, full epitope set | RhD-positive | RhD-positive; no RhIG needed |
| Partial D (e.g., DVI) | Missing specific epitopes | Usually RhD-positive | RhD-negative; RhIG-eligible |
| Serologic weak D, molecular type unresolved | Unknown | Refer for RHD genotyping | Manage as RhD-negative until resolved |
| All other rare/uncharacterized weak D types | Variable, unconfirmed risk | Case-by-case, typically RhD-positive | RhD-negative, out of caution |
Current joint guidance from AABB, CAP, ACOG, America's Blood Centers, and the American Red Cross recommends resolving every serologic weak D result in a transfusion recipient or a woman of childbearing potential with RHD genotyping rather than relying on serology alone. Individuals confirmed as weak D type 1, 2, 3, 4.0, or 4.1 can be managed safely as RhD-positive — they do not need RhIG and do not need to be reserved RhD-negative units — because high-quality evidence shows they are not meaningfully at risk of forming alloanti-D. All other, rarer, or as-yet-uncharacterized weak D types are managed conservatively as RhD-negative until further evidence justifies otherwise. This workflow (initial weak agglutination at the antihuman-globulin phase, referral for genotyping, then classification and rule application) is exactly the kind of multi-step decision the SBB exam tests candidates on, because it requires combining serologic recognition with genetics-based risk stratification.
Rh-null and Rh-mod Phenotypes
Inserting Rh polypeptides into the red cell membrane requires a partner protein, RhAG, encoded by RHAG on chromosome 6. Two distinct genetic mechanisms can eliminate Rh antigen expression entirely, producing the rare Rh-null phenotype:
- Regulator type — Mutations in RHAG itself silence Rh antigen expression even though the person's own RHD and RHCE genes are structurally normal, because without functional RhAG, the Rh polypeptides cannot be transported to the membrane.
- Amorph type — Mutations directly at the RH locus (RHD and RHCE themselves) eliminate Rh antigen production without any RHAG defect.
Because the RhAG-Rh complex also has a structural role in the membrane, Rh-null red cells commonly display stomatocytosis and a chronic, usually well-compensated hemolytic anemia. Rh-null individuals who become alloimmunized can develop anti-Rh29, an antibody directed against the entire Rh protein complex rather than a single antigen, which makes essentially all Rh-positive and ordinary Rh-negative red cells incompatible — these patients depend on rare-donor registries or autologous blood for transfusion support. A milder, partial version of RhAG deficiency produces the Rh-mod phenotype, with weak but detectable Rh antigen expression and a correspondingly milder clinical picture.
A blood donor's red cells serologically type as DVI, a partial D variant. How should the donor unit typically be labeled, and why?
Which molecularly confirmed weak D types can currently be managed safely as RhD-positive without RhIG or RhD-negative blood? Select all that apply.
Select all that apply
Put the steps for resolving a serologic weak D result in a transfusion recipient in the correct order.
Arrange the items in the correct order
An alloimmunized Rh-null patient develops anti-Rh29. What makes this antibody so difficult to manage from a transfusion standpoint?